Clevexel Pharma

Clevexel Pharma is a private, clinical-stage biotech company based in Paris, France, focusing on advancing novel therapeutic candidates to clinical proof-of-concept. The company leverages its expertise in drug development to identify and progress molecules with high potential, operating through a partnership-driven model. Its pipeline includes CVXL-0095 for reducing mucositis/dermatitis from cancer therapy and CVXL-0255, a dual SYK/JAK inhibitor for immuno-inflammatory conditions. Clevexel has been recognized as an innovative company by the Medicen Paris Region competitiveness cluster.

Expertise in early-stage drug design and development, focusing on novel galenic formulations (dosage forms/administration) and combination mechanisms of action to create differentiated therapeutics for unmet needs.

Total raised: $15M

Faces competition in supportive care from existing topical products and in immuno-inflammation from major pharma companies with approved JAK inhibitors (e.g., Pfizer, AbbVie, Eli Lilly). Clevexel's differentiation lies in its specific formulation approach (CVXL-0095) and dual-mechanism action (CVXL-0255), aiming to address limitations of current therapies.